Viacyte Receives Funding to Continue Developing Beta Cell Therapies
ViaCyte, a regenerative medicine company long-supported by Breakthrough T1D, today announced $27 million in financing to continue the development of…
Meet the Scientist: Local Immune Suppression with a Novel Protein
Mark Poznansky, M.D., Ph.D., wants the seemingly impossible—a person with type 1 diabetes (T1D) has a procedure where beta cells…
Public and Private Organizations, All with the Same Goal: End T1D
In this time of great uncertainty, there is some exciting news out of Europe. Innodia, a partnership between public and…
Breakthrough T1D Plays a Leadership Role, Again, to Marshal Resources for T1D Research
It’s 2004. The California Institute for Regenerative Medicine (CIRM), which will fund $3 billion in stem cell research to advances…
Meet the Scientist: Developing Devices That Resist Autoimmune Attacks
What might be the next best thing to having a healthy pancreas that is steadily producing insulin? It could be…
Coating on Capsules Next Step in Creating Insulin-Producing Factories
One potential cure for type 1 diabetes (T1D) is to replace beta cells destroyed by a person’s own immune system…
Strengthening Type 1 Diabetes Science by Building Careers
Sometimes, the funding that Breakthrough T1D can provide for researchers is exactly the invitation they need to get into the…
Breakthrough T1D Beta Cell Replacement Consortium: Partnerships and Paradigm Shifts
Last week’s Breakthrough T1D Beta Cell Replacement Consortium enabled 57 researchers the chance to collaborate in ways that help move…
Production of Insulin in People with Type 1 Diabetes
Sernova, a clinical-stage regenerative medicine company, has shown in its Breakthrough T1D-funded clinical trial that its cell replacement therapy, the…
Breakthrough T1D Brings Together Leading Experts at Islet Targeting Workshop
Breakthrough T1D is committed is to curing type 1 diabetes (T1D) through beta cell therapies, which is a complicated problem…
